Russia's First Bioactive Supplement Fights Age-Related Vision Loss Affordably

Russian scientists have developed the country's first domestically produced bioactive supplement aimed at preventing age-related macular degeneration (AMD). Created in Novosibirsk by Visus Lab, a resident of the Skolkovo innovation hub, the supplement offers a more affordable alternative to costly existing treatments. AMD remains a leading cause of irreversible vision loss in people over 50, affecting millions across Russia alone. The new supplement relies on omega-3 extracted from flaxseed, combined with a blend of micronutrients and antioxidants. Its formula includes resveratrol, lutein, dioxodin, chelated zinc, and L-lysine. To improve absorption, the product uses liposomal technology, which boosts bioavailability—a method gaining global recognition in dietary supplements.

Clinical trials involved two patient groups, with results showing an 85% improvement in retinal morphology and visual acuity. The supplement is designed for short-term use: one capsule taken twice daily over a month. This approach contrasts with current AMD treatments, such as eye injections, which often come with high costs. The rise of liposomal technology has reshaped the supplements market, with liquid formulations projected to grow from $24.68 billion in 2026 to $41.10 billion by 2034. Major markets like China and India are leading adoption, with liposomal products now appearing in specialised eye care and fat-soluble vitamin supplements. Meanwhile, experts like biologist Sergei Podkovalnikov suggest that advances in personalised medicine—including DNA-based treatments—could extend human lifespans to 150 years. Widespread clinical use of such technologies is expected within decades, driven by falling costs and improved accessibility.

The Novosibirsk-developed supplement provides a promising option for AMD prevention, particularly for those unable to afford expensive therapies. Its success also reflects broader trends in liposomal technology and personalised medicine, which are set to transform healthcare in the coming years. The product's availability marks a step forward in Russia's domestic biotech sector.